UBE2CP4: A Potential Drug Target and Biomarker (G283711)

Target Name: UBE2CP4

NCBI ID: G283711

UBE2CP4

Other Name(s): ubiquitin conjugating enzyme E2 C pseudogene 4 | Ubiquitin-conjugating enzyme E2C pseudogene 4

UBE2CP4: A Potential Drug Target and Biomarker

UBE2CP4, also known as ubiquitin conjugating enzyme E2 C pseudogene 4, is a protein that plays a crucial role in cellular processes essential for cell survival and function. UBE2CP4 is a member of the ubiquitin system, a protein-protein interaction network that is involved in various cellular processes, including cell signaling, DNA damage repair, and inflammation.

In recent years, researchers have become increasingly interested in UBE2CP4 as a potential drug target and biomarker. Its unique function and its potential to alter cellular behavior make it an attractive target for drug development.

Drug Target Potential

UBE2CP4 is a protein that can be targeted by small molecules, such as drugs, to modulate its activity and achieve desired cellular effects. One of the main advantages of targeting UBE2CP4 is its high sensitivity to small changes in its activity. This is due to its unique structure, which allows small molecules to interact with specific residues on the protein and alter its function.

In addition, UBE2CP4 is a good candidate for drug discovery because it has a large and well-studied gene. The human gene for UBE2CP4 has 1,345 amino acid residues and is located on chromosome 19 at position 368. This makes it accessible for small molecule screening and targeting.

Biomarker Potential

UBE2CP4 can also serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its involvement in cellular signaling processes makes it a potential indicator of disease progression.

For example, UBE2CP4 has been shown to be involved in the regulation of the T-cell receptor (TCR), which is a critical molecule in the immune response. UBE2CP4 has been shown to play a role in theTCR-CDK signaling pathway, which is critical for T-cell activation and proliferation.

In addition, UBE2CP4 has also been shown to be involved in the regulation of cell adhesion, a process that is critical for tissue repair and regeneration. Its involvement in this process makes it a potential biomarker for various diseases, including cancer.

Potential Therapeutic Strategies

Given its potential as a drug target and biomarker, researchers have explored various therapeutic strategies to target UBE2CP4. One of the most promising strategies is the use of small molecules that can inhibit UBE2CP4's activity.

One approach is to use inhibitors that target specific residues on UBE2CP4. These inhibitors can be designed to interact with UBE2CP4 and prevent it from doing its job. One example of an inhibitor that targets the alpha-helices region of UBE2CP4 is Q2, which is a small molecule that can inhibit the activity of UBE2CP4 in cell experiments.

Another approach is to use small molecules that can modulate UBE2CP4's activity by changing its conformation. This can be done by using molecules that can add or remove functional groups from UBE2CP4, such as linkers or amino acids that can modify the protein's activity.

Overall, UBE2CP4 is a protein that has great potential as a drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive target for drug development. Further research is needed to fully understand its function and develop effective therapies.

Protein Name: Ubiquitin Conjugating Enzyme E2 C Pseudogene 4

The "UBE2CP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2CP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets